Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9768MR)

This product GTTS-WQ9768MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9768MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15236MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TAK-079
GTTS-WQ4411MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-663513
GTTS-WQ4366MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-188667
GTTS-WQ15984MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ2876MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG-761
GTTS-WQ8788MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IBI-306
GTTS-WQ3733MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ6633MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DCDS0780A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW